Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
|Articles|March 17, 2023
News Roundup: March 13 to March 17
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
Novo Nordisk To Cut Insulin Prices Up To 75%
According to a company press release, the price reductions will go into effect at the start of 2024.
US District Judge Hearing Arguments to Potentially Halt Distribution of Abortion Pill Mifepristone
The decision could potentially limit abortion access for people all around the United States.
FDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine As Booster Dose For Young Children
A new booster shot of the Pfizer-BioNTech COVID-19 vaccine is now available for children aged 6 months to 4 years, in an effort to continue to curb the effects of COVID-19.
FDA Grants De Novo Approval to Non-Invasive Tinnitus Treatment Device
The product, called Lenire, uses bimodal stimulation and will be available in April 2023.
Nasal Spray For Migraines Gets FDA Approval
The spray, called Zavzpret, intends to help individuals who struggle with migraines but can't take oral medication because of nausea or vomiting.
Advertisement
Related to this article
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Advertisement
Advertisement
Trending on Drug Topics
1
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
2
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
3
Pharmacies Face Persistent MFP Cash Crunch Amid PBM, 340B Shifts
4
COVID-19, Flu Shots Coadministered Are Well-Tolerated in Pregnancy
5